Jefferies Starts Vaxcyte (PCVX) at Buy (Earlier)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Jefferies Starts Vaxcyte (PCVX) at Buy (Earlier)
July 7, 2020 9:21 AM EDT
BofA Securities analyst Jason Gerberry initiates coverage on Vaxcyte (NASDAQ: PCVX) with a Buy rating and a price target of $37.00.
The analyst cited three key reasons to like the stock: "1) Pneumococcal conjugate vaccine is the largest vaccine market with >$7bn/$8.5bn... More
July 7, 2020 6:52 AM EDT
(Updated - July 7, 2020 8:47 AM EDT)
(updated to add analyst comments)
Needham & Company analyst Alan Carr initiates coverage on Vaxcyte (NASDAQ: PCVX) with a Buy rating and a price target of $40.00.
The analyst commented, "Vaxcyte is leveraging a unique conjugation technology... More
July 7, 2020 3:36 AM EDT
(Updated - July 7, 2020 5:09 AM EDT)
(updating comment)
Cantor Fitzgerald analyst Louis Chen initiates coverage on Vaxcyte (NASDAQ: PCVX) with a Overweight rating and a price target of $55.00.
The analyst comments "We expect upward earnings forecast revisions and multiple... More
